Similarly, THP, an anthracycline anticancer drug, is clinically approved for treating various cancers and as a first‐line treatment chemotherapeutic for advanced HCC patients.6, 20 Interestingly, we found that THP could suppress MARCH1 expression in proteins. This evidence concerns the gene MARCHF1 and hepatocellular carcinoma.